Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Key Highlights
- ➤Q3 net revenues $1.?? billion, up 4.4% year over year
- ➤Q3 Adjusted EPS $0.29, up 12% per diluted share
- ➤2026 revenue outlook reaffirmed at 5.25%-6.75% constant-currency growth
- ➤2026 Adjusted EBITDA outlook reaffirmed at 5.75%-7.25% growth
- ➤Net leverage ratio improved to 2.9x from 3.2x at December 31, 2025
Expert Statements
Alton Shader, Chief Executive Officer of Sotera Health
“We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion.”
Alton Shader, Chief Executive Officer of Sotera Health
“Our performance was supported by year-over-year constant currency revenue growth of 8.2% at Sterigenics and 9.2% growth at Nelson Labs. We remain focused on being a trusted partner to our customers, combining exceptional service with the quality, reliability and technical expertise needed to support critical healthcare products and the patients who depend on them.”
Alton Shader, Chief Executive Officer of Sotera Health
“Based on our year-to-date performance and expectations for the remainder of the year, we are reaffirming our 2026 constant currency revenue and Adjusted EBITDA outlook.”
* Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis((1)), compared to Q3 2025 * Q3 2026 net income of $58 million or $0.20 per diluted share * Q3 2026 Adjusted EBITDA(()(1)()) increased 3.9%, or 4.0% on a constant currency basis * Q3 2026 Adjusted EPS((1)) of $0.29, an increase of 12% per diluted share * Reaffirming full-year 2026 net revenues growth outlook of 5.25% - 6.75% and Adjusted EBITDA growth outlook of 5.75% - 7.25%, both on a constant currency basis CLEVELAND, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2026.
“We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion,” said Alton Shader, Chief Executive Officer. “Our performance was supported by year-over-year constant currency revenue growth of 8.2% at Sterigenics and 9.2% growth at Nelson Labs. We remain focused on being a trusted partner to our customers, combining exceptional service with the quality, reliability and technical expertise needed to support critical healthcare products and the patients who depend on them.”
Get started
Create a free account to read the full story.